Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease 2023-12-06
  2. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia 2017-04-18

Studies

2 studies carry this tag.

Date range

2017 to 2023

Top journals

  • Clinical interventions in aging 1
  • Journal of basic and clinical physiology and pharmacology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of basic and clinical physiology and pharmacology 2023-12-06 Treatments

    The humanised monoclonal antibody donanemab is being developed to treat early onset Alzheimer's disease (AD).

  2. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Clinical interventions in aging 2017-04-18 Treatments

    Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD).

All topic tags with their study counts